1,721,148 research outputs found
Ocular complications in patients with psoriasis: Is dry eye associated with psoriasis?
Full text linkSafety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents
Full text linkIntroduction: There is very limited kn3e safety of COVID-19 vaccines in patients with psoriasis who are being treated with biological agents. We present our experience in 369 patients with moderate-to-severe psoriasis undergoing therapy with anti-IL agents who were vaccinated against SARS-CoV-2. Areas covered: None of the 369 patients referred to any serious adverse event related to vaccination against COVID-19, while about one-third reported mild adverse events similar to those seen in the general population that were resolved within 48 hours. No patient discontinued biological therapy to receive a COVID-19 vaccine. Expert opinion: Our observations provide evidence that COVID-19 vaccines can be considered safe in patients with moderate-to-severe psoriasis who are receiving anti-IL therapy
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections
No full textIntroduction: Acute bacterial skin and skin structure infections (ABSSIs), defined as a bacterial infection
of the skin with a lesion size area of at least 75 cm, are a leading cause of hospital admission and
ambulatory care visits worldwide. Dalbavancin is a lipoglycopeptide antibiotic recently approved by the
United States Food and Drug Administration (FDA) and by European Medicines Agency (EMA) for
ABSSSIs. The authors review and provide updates of efficacy and safety by several studies on
dalbavancin.
Areas covered: A PubMed search was performed for relevant literature. We especially focused our
attention on pharmacokinetics.
Expert opinion: Dalbavancin provides an important new therapy for management of ABSSI, maintaining
a spectrum of activity similar to vancomycin against gram-positive organisms. Use of dalbavancin,
with its 1-week-shot treatment, consist in a reduction of the length of hospital stay or in a reduction of
hospital admissions, with important cost savings
Brodalumab for the treatment of psoriasis
No full textIntroduction: Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL- 17RA monoclonal antibody, is currently the most-developed treatment that binds to the IL-17RA. The authors review and provide updates of efficacy and safety by several studies on brodalumab.
Areas covered: A PubMed search was performed for relevant literature. Among the trials of brodalu- mab, the most common adverse events included nasopharyngitis, headache, upper respiratory tract infection, and arthralgia. Suicidal ideation and completed suicides had been observed in the brodalu- mab programme, although evidence to date was quoted as not suggesting a causal association. Expert commentary: By blocking the IL-17 receptor A, brodalumab antagonizes signaling from IL-17A, IL-17F, IL-17A/F and IL-25, and this probably contributes to the high efficacy observed in clinical trials. Considering the different therapeutic target and the potential biological implications that blocking IL- 17RA instead of IL-17A might have, brodalumab may not necessarily belong to the same class that includes secukinumab and ixekizumab, but it may be classified in a distinct group
Tildrakizumab for treating psoriasis
No full textAgents that block inflammatory pathways other than tumor necrosis factor (TNF) have
represented new options for treating psoriasis in recent years. IL-23 is involved in regulating Th17 cells
and is a potent activator of keratinocyte proliferation. Targeting IL-23p19 alone may be a promising
treatment approach in patients with moderate-to-severe chronic plaque psoriasis, with a downregulation
of Th17 and Th22 cell responses, while IL-12 blockade is not required to achieve efficacy in these
patients.
Areas covered: The authors review and provide an update on tildrakizumab, a humanized IgG1
monoclonal antibody that blocks the p19 subunit of IL-23.
Expert opinion: Total skin clearance is an important treatment goal that has both measurable and
clinically meaningful benefits. Meeting patient needs about total clearance, IL-23p19 inhibitors will
obtain a specific position in the crowded psoriasis market. On the other hand, PASI 75 and PASI 90
response achieved by tildrakizumab in the phase II and III trials are less than the response achieved by
the IL-17A inhibitors and other p19 competitors, possibly due to a less intensive dosing regimen,
although direct comparisons cannot be made without a head-to-head randomized clinical trial. The
main advantage of tildrakizumab is that it is dosed in a maintenance regimen of 12 weeks, and similar
to ustekinumab, this is likely to encourage adherence and aid persistence to the drug
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era
No full textintroduction: In light of the current covid-19 pandemic and the ongoing, extensive debate about the use of biological agents in psoriatic patients, we felt compelled to relate our experience in the use of secukinumab in the same cohort before and during the lockdown in Italy.areas covered: secukinumab was not discontinued, and there were no cases of confirmed infection with SARS-CoV-2 in this cohort. expert opinion: In our practice, there is no evidence favoring the discontinuation of secukinumab in these patients. we also present a brief commentary on the use of biological agents in patients with moderate-to-severe plaque psoriasis
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
Full text link
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis
No full textBackground Advances in knowledge about the metabolic pathways involved in the pathogenesis of psoriasis and related diseases have led to a search for new therapeutic targets and the development of new biological drugs. Several studies have focused on HLA-C*06 and investigated correlations between the genetic risk factors of psoriasis and clinical parameters such as the severity of the disease and the response to treatment.Objective Our objective is to share experience from our institution in the observation of two patients with severe chronic plaque psoriasis who were unresponsive to any anti-TNF-alpha treatment and only partially responsive to ustekinumab. The patients are carriers of a rare allele of HLA-C that occurs in Caucasians.Methods The patients with moderate-to-severe chronic plaque psoriasis, and candidates for biological therapy were typed for the HLA-C locus at high resolution via polymerase chain reaction sequence-specific oligonucleotide probes (PCR-SSOP) using a commercial kit (LAB(A (R))Type, One Lambda Inc., Canoga Park, CA, USA). The socio-demographic variables and clinical data were collected.Results In our cohort of 134 patients, only two showed the presence of the allele HLA-C*18:01. To our knowledge, a coincidence between HLA-C*18 and severe psoriasis in Caucasian patients has not previously been described. The fact that both of these patients showed the same clinical history (unresponsive to any anti-TNF-alpha treatment and partially responsive to ustekinumab) cannot be attributed to a random observation because HLA-C*18 is extremely rare in Europe. As a consequence, at this latitude, it probably indicates a severe disease for which the proper therapy has still not been identified
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up
No full text- …
